A Phase II Study of Rituximab plus Lenalidomide for Untreated Mantle Cell Lymphoma

Full Title

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study


R-CHOP therapy (the anticancer drugs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-HIDAC (rituximab plus high-dose cytarabine) are treatments for an aggressive form of lymphoma called mantle cell lymphoma (MCL). Lenalidomide is a drug used to treat people with MCL whose cancer has continued to grow despite other treatments. In this study, researchers want to evaluate the safety and effectiveness of using lenalidomide as maintenance therapy after the other treatments have been completed, before the cancer comes back, as a way of reducing cancer recurrence in people with previously untreated MCL.

Patients in this study will first have R-CHOP plus lenalidomide, followed by R-HIDAC, and finally lenalidomide-rituximab as maintenance therapy. Researchers will also evaluate the use of minimal residual disease testing (a method to find very small amounts of lymphoma cells in the body) to predict a patient’s response to treatment.

Lenalidomide and prednisone are taken orally (by mouth). The other drugs in this study are given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have mantle cell lymphoma (stage 2 or greater) which has not yet been treated.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Anita Kumar at 212-639-2668.